drugset / Trial / NCT00504998
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.
Timeline
- Start
- 2007-07
- Primary completion
- 2010-07
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rexin-G | Unknown | 1e+11 unknown | Intravenous |
| Subject | Rexin-G | Unknown | 2e+11 unknown | Intravenous |
| Subject | Rexin-G | Unknown | 3e+11 unknown | Intravenous |
| Subject | Rexin-G | Unknown | 4e+11 unknown | Intravenous |